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Abstract: Background: The role of the neutrophil-to-lymphocyte ratio (NLR) of peripheral blood
has been investigated in relation to several autoimmune diseases. Limited studies have addressed
the significance of the NLR in terms of being a marker of disease activity in multiple sclerosis (MS).
Methods: This is a retrospective study in relapsing–remitting MS patients (RRMS) admitted to the
tertiary MS center of Catania, Italy during the period of 1 January to 31 December 2018. The aim of
the present study was to investigate the significance of the NLR in reflecting the disease activity in a
cohort of early diagnosed RRMS patients. Results: Among a total sample of 132 patients diagnosed
with RRMS, 84 were enrolled in the present study. In the association analysis, a relation between
the NLR value and disease activity at onset was found (V-Cramer 0.271, p = 0.013). In the logistic
regression model, the variable NLR (p = 0.03 ExpB 3.5, CI 95% 1.089–11.4) was related to disease
activity at onset. Conclusion: An elevated NLR is associated with disease activity at onset in RRMS
patients. More large-scale studies with a longer follow-up are needed.
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1. Introduction
Multiple sclerosis (MS) is a chronic autoimmune disease of the central nervous system (CNS),
in which inflammation, demyelination, and axonal loss coexist, manifesting in a plethora of clinical signs
and symptoms [1]. Regarding its pathogenesis, it has been suggested that autoreactive myelin-specific
T cells may trigger and modulate the access and trafficking of inflammatory leukocytes to the CNS.
Increasing evidence also suggests a fundamental role of B cells in the pathogenesis and development
of MS [2].
Neutrophils are bone-marrow-derived cells that represent the most abundant peripheral blood
leucocyte and are able to generate extracellular traps, which can be proinflammatory and provide a
potential source of autoantigens, triggering autoimmunity [3]. The contribution of neutrophils to CNS
autoimmune diseases was first suggested by studies on experimental autoimmune encephalomyelitis
(EAE), the animal model of MS, in which neutrophils delayed the onset and decreased the severity of
EAE [3–6].
Cells 2019, 8, 1114; doi:10.3390/cells8101114 www.mdpi.com/journal/cells
Cells 2019, 8, 1114 2 of 8
The role of the neutrophil-to-lymphocyte ratio (NLR) of the peripheral blood in several autoimmune
diseases has recently been suggested as a potential cheap and effective surrogate marker for the systemic
inflammatory state and thus disease activity [5]. Few studies have addressed the significance of the
NLR in terms of being a marker of disease activity in MS [7–9].
The aim of the present study was to investigate the significance of the NLR in reflecting the level
of disease activity in a cohort of early diagnosed relapsing–remitting MS (RRMS) patients.
2. Materials and Methods
The iMED© software (6.5.6, Merck Serono SA, Geneva, Switzerland) was used as the data entry
portal, and we followed a rigorous quality assurance procedure to ensure data quality.
The inclusion criteria were: 1) in the age range of 18 to 55 years old; 2) a diagnosis of RRMS
according to the 2017 McDonald criteria (retrospectively evaluated at the end of the diagnostic-iter) [10].
The exclusion criteria were: 1) short-term steroid use in the last 30 days; 2) recent infections
(≤1 month); 3) stressful concomitant events in the last 6 months (e.g., traumatic bone fractures); 4)
a history of tumors; 5) pregnancy; 6) confirmed autoimmune comorbidities (rheumatoid arthritis,
psoriasis, Sjögren syndrome, etc.) (Figure 1).
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2.1. Clinical Data
Data were collected from each patient at the time of enrollment, defined as the first access to a
diagnostic MS center prior to setting a confirmed MS diagnosis or starting any disease-modifying
therapy (DMT).
The data collected were the following: demographic data, including patient age and gender,
clinical data including the date of MS onset, type of MS, number of relapses in the year prior to
diagnosis, and level of disability assessed by the Expanded Disability Status Scale (EDSS) in the year
prior to diagnosis [11]. As a radiological measure of disease activity, we considered the number of
brain and spinal lesions detected on T1 gadolinium (Gd) magnetic resonance imaging (MRI) sequences
(Ingenia 1.5 Tesla-Philips®). Lesions and imaging were compared with the support of available
software (Carestream® Healthcare Information Systems software).
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Patients consecutively included in the present study were divided into two groups—low (L)
and high disease activity (H), according to the level of disease activity in the year prior to diagnosis,
and considering the definition of highly active MS in patients naïve to DMT [12–15].
High disease activity at onset was classified as: ≥2 relapses in the year prior to study entry and ≥1
Gd-enhancing lesion at the time of study [12–15].
2.2. Blood Tests
Blood cell counts of neutrophils and lymphocytes were obtained via routine blood sampling,
as part of the clinical practice in each enrolled patient. The last blood test values from immediately
prior to commencement of the first DMT were used, and blood tests taken within 30 days of the start of
short-term steroid treatment for relapse were excluded.
Blood sampling was performed between 8.00 and 8.30 a.m. and collected in
dipotassium-ethylenediaminetetraacetic acid tubes. Samples were analyzed within 40 min to 1 h of
collection. A complete blood count (CBC) was obtained using a blood count machine (ABX micros 60,
Horiba medical®).
2.3. Outcomes
The primary aim of the present study was to investigate, in a real-world setting, whether the NLR
is related to high disease activity at the time of disease onset.
2.4. Ethical Standards
The study protocol was approved by the Local Ethics Committee (Comitato Etico Catania
1, n.17/2019/PO). All patients provided written informed consent. The present study was
conducted in accordance with the ethical principles of the Declaration of Helsinki and appropriate
national regulations.
2.5. Statistical Analysis
All patient characteristics summary statistics are reported in terms of frequencies (%) for categorical
variables, mean ± standard deviation (SD), or median with interquartile range (IQR) for continuous
variables. The NLR was calculated as the quotient between the neutrophil and lymphocyte cell counts
in blood. The distribution of the NLR was, as expected for a quotient, highly skewed. Therefore,
in order to correct for skewness, a log transformation of the NLR was considered. The resulting
transformed data show an approximatively Gaussian distribution. Normality assumption has been
assessed by using both visual methods (Q-Q plot) and the Kolmogorov–Smirnov (K–S) normality
test. Associations between qualitative variables were analyzed using Pearson’s X2 tests. In order to
express results as a percentage of the maximum possible variation, the V-Cramer index was used
instead of the X2 test. This index can vary between 0 (in the case of independence) and 1 (in the case
of maximum association). Several associations were evaluated: between the log-NLR (ln-NLR) and
gender, age, EDSS value, and disease activity, respectively. Each variable was treated as categorical
according to literature cut-off and the quantile of the observed distributions. In particular, the ln-NLR
was dichotomized as 0 for ln-NLR values of ≤0.6 and 1 when ln-NLR was >0.6; gender was defined
as 0 for Male and 1 for Female; 40 was the cut-off used for age (0 when age was ≤40 and 1 when
age was >40); the EDSS categories were 0 (when the EDSS value was ≤3.5) and 1 (when the EDSS
value was >3.5); disease activity as 0 (group L/low disease activity) and 1 (group H/high disease
activity). A logistic regression model was used to study the relationship between disease activity
(0 = group L, 1 = group H) and the following variables: gender, age (expressed as a continuous variable),
ln-NLR expressed as a continuous variable, and the EDSS value. Logistic regression assumptions were
verified; the outcome was a binary variable and no high correlations among predictors were observed.
All analysis was performed using the SPSS version 21 statistical software (IBM SPSS Statistics 21, IBM,
Armonk, NY, USA).
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3. Results
Among a total sample of 132 RRMS patients, 84 fulfilled the required inclusion criteria and were
enrolled in the present study (Figure 1). Of these, 38 were in group L and 46 in group H. Patient
demographic and clinical characteristics are shown in Table 1. Patients in group H showed a higher
EDSS score at disease onset (p = 0.020). Blood tests showed that the ln-NLR ratio was highest in
patients in group H (1 ± 0.4 vs. 0.7 ± 0.4, p = 0.032) (Figure 2).
Table 1. Demographical and clinical characteristics of the two groups at disease onset.
Group L (n = 38) Group H (n = 46) P-Value
Men 19 (50%) 19 (41.3%) 0.42
Women 19 (50%) 27 (58.7%)
AGE 43 ± 13.4 36.9 ± 12.5 0.23
L% 29 ± 8.5 27.8 ± 6.6 0.95
N% 62.3 ± 7.7 63.3 ± 7.7 0.57
lnNLR 0.7 ± 0.4 1 ± 0.4 0.032
EDSS value 1.5 (1.0–3.0) 2.5 (1.0–5.0) 0.020
Results are expressed as mean ± SD, median (IQR) and No. (%). IQR = interquartile range; SD = standard
deviation. Abbreviations: EDSS, Expanded Disability Status Scale; L, lymphocytes, N, neutrophils; ln-NLR,
logarithmic-neutrophils/lymphocyte ratio.
Cells 2019, 8, 1114 4 of 8 
 
correlations among predictors were observed. All analysis was performed using the SPSS version 21 
statistical software (IBM SPSS Statistics 21, IBM, Armonk, NY, USA). 
3. Results 
Among a total sample of 132 RRMS patients, 84 fulfilled the required inclusion criteria and were 
enrolled in he present study (Figure 1). Of these, 38 were in group L and 46 in group H. Patient 
demograp ic and clinical characteristics are shown in Table 1. Patients in group H showed  higher 
EDSS score at disease onset (p = 0.020). Blo d tests showed that the ln-NLR rati  was highest in 
patients in group H (1 ± 0.4 vs. 0.7 ± 0 4, p = 0.032) (Figure 2). 
Table 1. Demographical and clinical characteristics of the two groups at disease onset. 
 Group L (n = 38) Group H (n = 46) P-Value 
Men 19 (50%) 19 (41.3%) 0.42 
Women 19 (50%) 27 (58.7%)  
AGE 43± 13.4 36.9 ± 12.5 0.23 
L% 29 ± 8.5 27.8 ± 6.6 0.95 
N% 62.3 ± 7.7 63.3 ± 7.7 0.57 
lnNLR 0.7 ± 0.4 1 ± 0.4 0.032 
EDSS value 1.5 (1.0–3.0) 2.5 (1.0–5.0) 0.020 
Results are expressed as mean ± SD, median (IQR) and No. (%). IQR = interquartile range; SD = 
standard deviatio . Abbreviatio s: E SS, Expanded Disability Status Scale; L, lymphocytes, N, 
neutrophils; ln-NLR, logarithmic-neutrophils/lymphocyte ratio. 
 
Figure 2. Box plot of the ln-NLR in the two groups. Group L, Low disease activity; Group H, High 
disease activity; ln.NLR, log transformation of the neutrophil to lymphocyte ratio. 
The association analysis revealed a V-Cramer of 0.271 with a p-value of 0.013 between disease 
activity and the ln-NLR value (Figure 3). No associations were found between the ln-NLR value and 
other demographical and clinical variables (Table 2). In the regression logistic regression model, the 
relation between the highest ln-NLR and disease activitywas maintained (p = 0.03 expB 3.5, CI 95% 
1.089−11.4) (Table 3). 
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The association analysis revealed a V-Cramer of 0.271 with a p-value of 0.013 between disease
activity and the ln-NLR value (Figure 3). No associations were found between the ln-NLR value
and other demographical and clinical variables (Table 2). In the regression logistic regression model,
the relation between the highest ln-NLR and disease activitywas maintained (p = 0.03 expB 3.5, CI 95%
1.089–11.4) (Table 3).
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Figure 3. Association analysis between disease activity and the ln-NLR. Group L, Low disease activity;
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Table 2. Association analysis between the ln-NLR and demographical/clinical parameters.
Patient Characteristics vs. ln-NLR V-Cramer Index P-Value
Gender 0.016 0.289
Age 0.052 0.637
Disease activity 0.271 0.013
EDSS value at onset 0.062 0.567
Table 3. Logistic regression model for disease activity at onset.
Exp B P-Value Confidence Interval (95%)
Lower Upper
Gender 0.887 0.778 0.352 2.18
Age 1.00 0.555 1.00 1.00
ln-NLR 3.5 0.03 1.08 11.4
EDSS value at onset 1.00 0.926 1.00 1.00
4. Discussion
We found that a higher NLR value increased the risk of disease activity in our cohort. The NLR is
employed as a marker of systemic inflammation in other autoimmune diseases and cancers, since it is a
low-cost analysis [5,6]. A study using the EAE animal model of MS showed that neutrophil depletion
led to a reduction in the severity of the disease [16].
Ne trophils are short-lived, bone-marrow-derived cells, and are the most abundant peripheral
blood leucocytes. The number and lifespan of neutrophils are under tight control. Neutrophils are
phagocytic and microbiocidal, releasing tissue-remodeling enzymes and reactive oxidative species,
as well as proinflammatory cytokines and chemokines, which can provide a potential source of
autoantigens, triggering autoimmunity [3,5]. In other fields, such as rheumatoid arthritis, several
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studies have suggested that joint destruction and disease activity are directly correlated with the
recruitment of neutrophils in the synovium [17].
Few studies have investigated the association of the NLR with disease activity in MS patients in a
real-world setting. The role of neutrophil counts in MS is a recent and interesting challenge, focusing
on the involvement of the innate immune system [18].
Findings are available for MS and optic neuritis (ON) patients as compared with healthy controls
(HC) in a large Danish cohort. The NLR was found to be higher in MS and ON patients as compared to
HC, indicating the occurrence of chronic inflammation. The NLR may be an inexpensive and easily
accessible supplemental marker of disease activity in RRMS patients, revealing an association between
a high NLR value and MS occurrence as compared with controls [7,9,18]. Furthermore, a higher NLR
during relapse as compared to that during remission was shown in a study by Demirci et al., in which
the NLR predicted activity with 67% sensitivity and 97% specificity [7], indicating the value of NLR use
in measuring disease activity [7]. Furthermore, NLR has also been investigated as a possible marker
relating to the depression, anxiety, and stress score in MS patients [19].
Naegele et al. demonstrated that the increase in neutrophil count in RRMS patients is most likely
due to a decrease in apoptosis, and that neutrophils have an altered cell surface expression of certain
proteins, which may enhance recruitment to sites of inflammation [4].
However, there are a lack of available data regarding the prediction of long-term disease
progression, according to a high NLR ratio. Two previous studies found that the NLR correlates with
the EDSS value [7,8], whilst another found no association [18]. Interestingly, Hemond et al. investigated
the association of the NLR ratio with clinical, neuroimaging, and psycho-neuro-immunological
associations in a large cohort of MS patients, also including patient-reported outcomes. Here,
NLR strongly predicted increased MS-related disability independent of all demographic, clinical,
treatment-related, and psychosocial variables (p < 0.001) [20]. Moreover, Giovannoni et al. failed to
find a correlation between the mean levels of several proinflammatory immunological markers and
clinical disease progression [21]. Therefore, to further clarify whether the NLR is associated with MS
disability, studies with long follow-up times are needed, since this would enable measurement of
disease progression. The use of a marker obtained from a simple routine blood exam could make the
NLR ratio a useful supplemental biomarker of disease activity in MS patients in clinical practice.
The present study has some limitations, many of which are related to the retrospective design
and small sample size. The results build on simple data from routine laboratory tests, and, therefore,
may be biased toward the availability of certain laboratory data. Furthermore, there exists no data
regarding concomitant diseases that could alter the neutrophil count, or other data such as smoking
status. Prior to any possible use of the NLR in clinical practice, more data, preferably from multi-center,
long-term studies, are needed. Studies comparing the NLR with MRI and cerebrospinal fluid markers
would also be desirable. Additionally, the impact of disease-modifying drugs on the NLR is required
to establish the clinical application of this parameter. The NLR has gained academic relevance,
contributing to the knowledge of MS immunology.
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